|
|
Article: No Evidence of Cardiovascular Safety Signal for Pfizer's Celebrex in Long-Term Clinical Trials of More Than 6,000 Patients.
- Article from:
- PR Newswire Europe
- Article date:
- October 1, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK, October 1 /PRNewswire/ --
- 'Data demonstrate that Celebrex does not increase the risk of heart attack or stroke in patients with arthritis and pain, even at higher-than-recommended doses'
Pfizer Inc said today that three large long-term Celebrex (celecoxib capsules) studies involving more than 6,000 patients have not shown any significant safety issues and are expected to continue to completion.
The ongoing studies, which are assessing Celebrex as a potential preventative treatment in both Alzheimer's disease and colorectal cancer, have been under way at multiple medical centers worldwide for several years. The studies are being ...